You are here


This offering has completed and is not accepting investments.
Go to our Home page



The Genprex IPO to fund clinical trials of their gene therapy lung cancer treatment has completed, the stock is now trading on the NASDAQ with the ticker symbol GNPX

Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

This information has been gathered from the company's offering prospectus. Please review the S-1 Registration Statement. 

Rodney Varner

Rodney Varner is a co-founder of Genprex and has served as our President, Chief Executive Officer and Secretary, and as a member of our board of directors and as Chairman of our board of directors since August 2012. Mr. Varner served as a partner of the law firm Wilson & Varner, LLP, since 1991. Mr. Varner has more than thirty-five years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr. Varner has represented for-profit and non-profit companies at the board of directors or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers,licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr. Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr. Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. He is a registered securities representative and founder of a company that is a licensed securities broker-dealer. Mr. Varner holds Series 7, 24, 63, and 79 securities registrations. Mr. Varner received his BBA, with high honors, from Texas A&M University and his J.D. from The University of Texas School of Law.

Julien Pham, MD, MPH

Julien L. Pham, MD, MPH has served as our Chief Operating Officer since October 2016. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases, and served as its Chief Medical Officer from March 2013 to September 2016. Prior to co-founding RubiconMD, Dr. Pham served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital, where he joined as a fellow in July 2008 and became an Associate Physician in the Division of Nephrology in August 2011. Dr. Pham has over fifteen years of leadership experience in clinical settings and in emerging medical technology companies. During this time, he has held various research and teaching positions including Chief Residency in Internal Medicine and Pediatrics at the University of Illinois at Chicago Medical Center, and has received multiple awards including excellence in teaching awards from AOA and Harvard Medical School. He is a board-certified internal medicine doctor and nephrologist. Dr. Pham has received NIH research funding for translational research while at Harvard Medical School, and he has published in basic science, translational, and health policy fields. He holds a BS in Cell and Molecular Biology from University of Washington and received his MD from the University of Washington School of Medicine and his MPH at the Harvard School of Public Health.

Ryan Confer

Ryan M. Confer has served as our Chief Financial Officer since September 2016. From December 2013 through September 2016, he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr. Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over ten years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Mr. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

David E. Friedman

David E. Friedman has served as a member of our board of directors since August 2012. Since August 2010, Mr. Friedman has served as a partner of TCG Group Holdings, an Austin, Texas based SEC-registered investment advisor to separately-managed institutional and private client accounts. In addition, since January 2012, Mr. Friedman has served as a managing partner of ACM Investment Management, which manages hedge fund assets acquired from KeyCorp, the bank holding company parent of KeyBank. From 2006 to 2010, Mr. Friedman served as the Chief Operating Officer of Austin Capital Management, which was owned by KeyCorp, where he led the company’s non-investment functions, including all legal, finance, investor relations, technology and operations teams. Before joining Austin Capital, Mr. Friedman was a Director on the Global Prime Brokerage desk of Citigroup in New York, and an associate at the law firm of Proskauer Rose in its New York headquarters. Mr. Friedman received his BS in management from Tulane University and his JD from Duke University School of Law. He is admitted to the Bar of the State of New York and holds FINRA Series 4, 7, 24 and 63 securities registrations. We believe that Mr. Friedman’s unique and valuable mix of high-level and relevant finance, legal and operations experience makes him a well-rounded business leader and a valuable member of our board of directors

Robert E. Pearson

Robert W. Pearson has served as a member of our board of directors since July 2012. In June 2009, Mr. Pearson joined W2O Group, a global network of complementary marketing, communications, research and development firms, and has held a number of senior positions at W2O Group, including Chief Technology Officer, President and since February 2017, Vice Chair and Chief Innovation Officer. From March 2012 to February 2017, Mr. Pearson served as President of W2O, and from June 2009 to March 2012 as its Chief Technology & Media Officer. From 2007 to 2009, Mr. Pearson served as Dell Inc.’s Vice President, Communities and Conversations, and before that as its Vice President, Corporate Group Communications. From 2003 to 2006, Mr. Pearson served as Head of Global Corporate Communications and as Head of Global Pharma Communications at Novartis Pharmaceuticals, where he also served on the Pharma Executive Committee. Before joining Novartis, Mr. Pearson served as President, The Americas and Chair, Healthcare Practice for GCI Group, a global public relations consultancy, and was responsible for creating and building the firm’s global healthcare practice. Mr. Pearson previously served as Vice President of Media and Public Affairs at Rhone-Poulenc Rorer, or RPR (now Sanofi-Aventis) and worked at RPR and Ciba-Geigy in communications and pharmaceutical field sales. Mr. Pearson holds a BA from the University of North Carolina at Greensboro and an MBA from Fairleigh Dickinson University. We believe that Mr. Pearson’s senior management experience at international pharmaceutical companies and public relations/ investor relations firms, as well as with start up businesses, and his knowledge and personal contacts in the pharmaceutical industry, and his business management acumen, make him a valuable member of our board of directors

James E. Rothman, Ph.D

James E. Rothman, Ph.D. has served as a Strategic Advisor to our board of directors since July 2012. Dr. Rothman serves as Sterling Professor and Chair of the Department of Cell Biology at Yale University School of Medicine, where he has been employed since July 2008. From 2003 to 2007, he served as chief scientist and executive committee member at GE Healthcare, a unit of General Electric Corporation, and held similar positions at Amersham plc prior to its acquisition by GE. Dr. Rothman was awarded the 2013 Nobel Prize in Physiology or Medicine and has received numerous other honors including the Lasker Basic Research Award. Previously, Dr. Rothman held endowed chairs at Memorial Sloan-Kettering Cancer Center, where he also served as Vice Chair of the Sloan-Kettering Institute, at the College of Physicians and Surgeons at Columbia University, and at Princeton University. He is a member of the US National Academies of Sciences and Medicine and a Fellow of the American Academy of Arts and Sciences. Dr. Rothman received his B.A. from Yale College and his Ph.D. in Biological Chemistry from Harvard University, where he also attended Harvard Medical School.


This information has been gathered from the company's offering prospectus. Please review the S-1 Registration Statement.

Genprex has assembled a world-class scientific and medical advisory board, widely recognized as experts in cancer metabolism, oncology, drug discovery and translational medicine. These advisors work in close collaboration with Genprex to identify new research directions and accelerate Genprex’s target validation, drug discovery and development strategies and programs.

Scientific & Medical Advisory Board

Jack A. Roth, MD, FACS, Chairman

Jack A. Roth, MD, FACS,is the Chairman of our SMA Board. Dr. Roth is an internationally renowned cancer expert and oncology pioneer. He is Professor and Distinguished Chair of Thoracic Surgery, Professor of Molecular & Cellular Oncology, Director of the Keck Center for Innovative Cancer Therapies, and Chief of Section of Thoracic Molecular Oncology at The University of Texas MD Anderson Cancer Center. Dr. Roth is a prolific inventor and the author of more than 600 peer reviewed publications. He is a pioneer in the clinical use of DNA as a therapeutic agent. He is the first clinical investigator approved by the FDA and NIH-RAC to conduct direct patient gene therapy clinical trials. Dr. Roth has over 20 years' experience in developing new cancer therapeutics for commercial application and is an inventor of our key intellectual property.

George R. Simon, MD

George Simon, MD, is a Professor of Medicine and Section Chief, Translational Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, where his principal focus includes translational research in lung cancer to predict the most effective therapeutic options based upon a tumor’s molecular profile.

Pasi Antero Janne, MD, PhD

Pasi Antero Janne, MD, PhD,is an Associate Professor of Medicine at Harvard Medical School and a clinician at Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology. Dr. Janne is a leading researcher in medical oncology and lung cancer and is Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer Center. His research includes the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents, as well as mechanisms of sensitivity and resistance targeted cancer therapies

Tony S.K. Mok, BMSc, MD, FRCPC, FHKCP, FHKAM (Medicine)

Tony S.K. Mok, BMSc, MD, FRCPC, FHKCP, FHKAM (Medicine) is a professor in the Department of Clinical Oncology at the Chinese University of Hong Kong in Prince of Wales Hospital in Hong Kong. Dr. Mok formerly served as President of the International Association for the Study of Lung Cancer (IASLC), Vice-Secretary General of the Chinese Society of Clinical Oncology (CSCO) and Co-Founder of the Lung Cancer Research Group, a multicenter organization serving the Asian-Pacific region.



This information has been gathered from the company's offering prospectus. Please review the S-1 Registration Statement.

Key IPO Data

$ 5.00


How it works

Step 1

Watch the Video, Review the Prospectus and Click "Invest Now"
If you need assistance please call to speak with a representative at Network 1 Financial Securities.


Step 2

Register to Participate and Open Account to Buy Shares
By opening an account with Network 1 you will be able to purchase shares and be up to date on the orders status, and keep track of the orders you have previously made.


Post comment

James Ryan on November 13
Hi I am James Ryan, I am an Investment Advisor dedicated to providing quality, personalized financial guidance to entrepreneurs and strategic partnerships. Kindly email a copy of your business plan/executive summary (Pitch deck) to an accredited angel investor who would be interested in financing your business deal and support project proposal. Name: Dr Hikoo Hayashi Email: ( [email protected] ) I have the financial planning strategies and investment solutions to help you achieve those goals. Regards James Ryan, CPA, EMBA

Genprex has paid $15,000 for consulting fees plus warrants, and has no future obligations. 100% of the cash received from consulting fees has been donated to the Bonnie J. Addario Lung Cancer Foundation. MSC will also donate 100% of any gain we make on the warrants to the same charity.